Avro’s TopiqIL platform technology utilises biocompatible ionic liquid pairs derived from some of the body’s natural building blocks to facilitate lipid extraction in the stratum corneum and epidermis, which serve as the largest barriers to dermal delivery.
In contrast to conventional permeation enhancers which work on the principles of lipid fluidization, our tech extracts lipids from the skin and washes them out, replacing the lipid content with formulation and water, forming a non-toxic and safe depot of the payload deep within the skin’s layers.
Our ionic liquid combinations allow for the encapsulation and where relevant, complexation of a variety of payloads for localized or intracellular delivery into the skin.
At the moment, there is no way to effectively deliver the next generation of nucleic acid therapeutics into the skin in a safe and patient-compliant manner. Procedures in clinical trials require diseased skin biopsies, culturing, transfection and skin grafts, or injections, dermarolling and or pre-treatment that is often impossible in application due to the features of the disease state being treated. Furthermore, it’s currently impossible to deliver a nucleic acid therapy targeted to the skin systemically, in the same way as one might deliver a protein or antibody intravenously.
Countless next-gen dermal therapies under development are left without an enabling vehicle to reach patients. Avro’s technology solves this, delivering these large, charged and complex molecules through the skin, directly into the site of action. Our team is developing proof of concepts across a number of therapeutic modalities including: